#United States #Irvine #LiverRight #Helio Genomics #LiverTrace

Helio Genomics and LiverRight Join Forces for Early Liver Cancer Detection

In a significant move to enhance liver cancer detection efforts across the United States, Helio Genomics, a techbio company renowned for its innovative diagnostics technology powered by artificial intelligence, has formed a strategic partnership with LiverRight, the nation’s first and only National Virtual Clinic dedicated to liver disease in adults. This partnership aims to broaden access to early liver cancer detection through Helio's advanced blood-based test, LiverTrace, and connect patients with certified hepatologists.

A New Approach to Liver Health

Every year, liver disease impacts nearly one-third of U.S. adults, significantly affecting the overall health of the population. Metabolic dysfunction-associated steatotic liver disease (MASLD) alone affects about 30% of adults, and yet it, along with other liver-related conditions, often goes undiagnosed. Delays in diagnosis can pose serious risks and hinder timely treatment, making early detection crucial.

Dr. Bharat Tewarie, CEO of Helio Genomics, emphasizes that in the field of hepatocellular carcinoma (HCC), time is of the essence. He notes, "Delays in diagnosis can be the difference between a curable condition and a life-threatening battle. Our collaboration with LiverRight will ensure that patients receive timely access to specialists when it matters most."

The technological synergy between Helio's LiverTrace test and LiverRight's central network of hepatology specialists is designed to provide patients with a streamlined pathway from identification to expert care. Leveraging AI and machine learning, LiverTrace can identify cancer biomarkers through a simple blood test, often before a tumor becomes detectable via imaging techniques like ultrasound.

How the Partnership Works

With the integration of LiverTrace into LiverRight's services, individuals who receive positive results can promptly consult with board-certified hepatologists and expert practitioners for further evaluation. This direct connection significantly reduces the time taken for diagnosis and treatment initiation, addressing previous bottlenecks that patients encountered.

Brandon Tudor, CEO of LiverRight, explains, "Historically, liver cancer diagnosis relied primarily on imaging procedures, but LiverTrace represents a groundbreaking noninvasive option, creating a vital entry point into the diagnostic process."

Convenient Testing at Home

LiverTrace is specifically designed for adults at heightened risk for liver cancer, including those with a family history of the disease or lifestyle factors known to increase risk. The process is straightforward: patients can order a blood collection kit online, which is then sent directly to their homes. A professional phlebotomist visits at a time convenient for the patient to collect the blood sample. Results are provided through a secure online portal within just two weeks. Additionally, an assessment tool is available on the LiverTrace website to help individuals determine their risk factors for liver cancer.

Early detection can make a critical difference in patient outcomes. Dr. Alexander Lalos, Chief Medical Officer of LiverRight, highlights the remarkable potential cure rates when liver cancers are diagnosed at an early stage, noting, “When caught early, several curative treatment options, including liver transplantation, can lead to five-year survival rates surpassing 70%. In stark contrast, advanced-stage liver cancer drastically reduces survival chances.”

Shared Vision for Improved Outcomes

This partnership underscores a mutual commitment between Helio Genomics and LiverRight to revolutionize liver cancer outcomes by removing barriers to early detection and ensuring timely specialist care. Both organizations are dedicated to transforming how liver diseases are diagnosed and treated, aiming for a future where delays in care are drastically minimized.

About Helio Genomics

Helio Genomics is at the forefront of AI-driven diagnostics, focusing on early cancer detection and the monitoring of minimal residual disease. With a deep learning and machine learning-based platform, Helio's innovative technology allows for unprecedented precision in detecting cancer biomarkers, enabling swift actions in the fight against liver cancer.

For more insights into Helio Genomics and its groundbreaking work, visit www.heliogenomics.com.

About LiverRight

LiverRight stands as a pioneer in telemedicine-focused liver disease care, providing comprehensive services across all 50 states. The clinic aims to ensure early diagnosis and effective treatment for various liver conditions, enhancing patient outcomes through a robust network of specialists. To learn more, explore www.liverright.com.